{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:59:10Z","timestamp":1791644350016,"version":"4.3.4"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/tp.0000000000001452","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T17:20:39Z","timestamp":1471627239000},"page":"32-44","source":"Crossref","is-referenced-by-count":247,"title":["Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection"],"prefix":"10.1097","volume":"101","author":[{"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jua","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonga","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210211","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"R2-14-20210211","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"R3-14-20210211","first-page":"5","article-title":"The molecular biology of interleukin 6 and its receptor","volume":"167","author":"Kishimoto","year":"1992","journal-title":"Ciba Found Symp"},{"key":"R4-14-20210211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","author":"Liu","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R5-14-20210211","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"R6-14-20210211","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R7-14-20210211","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"R8-14-20210211","doi-asserted-by":"crossref","first-page":"e0145258","DOI":"10.1371\/journal.pone.0145258","article-title":"Increase of Th17 cell phenotype in kidney transplant recipients with chronic allograft dysfunction","volume":"10","author":"Chung","year":"2015","journal-title":"PLoS One"},{"key":"R9-14-20210211","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ajt.13644","article-title":"HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion","volume":"16","author":"Lion","year":"2016","journal-title":"Am J Transplant"},{"key":"R10-14-20210211","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1681\/ASN.2014111147","article-title":"IL-6 trans-signaling drives murine crescentic GN","volume":"27","author":"Braun","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R11-14-20210211","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"key":"R12-14-20210211","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(14)71105-2","article-title":"Harnessing GVHD by interleukin-6 receptor blockade","volume":"15","author":"Finke","year":"2014","journal-title":"Lancet Oncol"},{"key":"R13-14-20210211","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nbt0908-957","article-title":"Actemra poised to launch IL-6 inhibitors","volume":"26","author":"Melton","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R14-14-20210211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6\u2013deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"R15-14-20210211","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"R16-14-20210211","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cmet.2015.02.006","article-title":"Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance","volume":"21","author":"Kraakman","year":"2015","journal-title":"Cell Metab"},{"key":"R17-14-20210211","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1159\/000439214","article-title":"Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer's disease","volume":"5","author":"Wu","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"R18-14-20210211","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R19-14-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int Immunol"},{"key":"R21-14-20210211","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","article-title":"Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6","volume":"180","author":"Puel","year":"2008","journal-title":"J Immunol"},{"key":"R22-14-20210211","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e31825f95b9","article-title":"Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey","volume":"91","author":"Chandesris","year":"2012","journal-title":"Medicine (Baltimore"},{"key":"R23-14-20210211","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12038-012-9202-x","article-title":"STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6\/STAT3 signalling pathway","volume":"37","author":"He","year":"2012","journal-title":"J Biosci"},{"key":"R24-14-20210211","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijbs.4666","article-title":"Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases","volume":"8","author":"Tanaka","year":"2012","journal-title":"Int J Biol Sci"},{"key":"R25-14-20210211","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/ejh.12646","article-title":"Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies","volume":"96","author":"Jerkeman","year":"2016","journal-title":"Eur J Haematol"},{"key":"R26-14-20210211","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","article-title":"IgG1 plasmacytosis in interleukin 6 transgenic mice","volume":"86","author":"Suematsu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-14-20210211","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.4238\/2015.October.16.16","article-title":"Association of interleukin gene polymorphisms with the risk of coronary artery disease","volume":"14","author":"Yang","year":"2015","journal-title":"Genet Mol Res"},{"key":"R28-14-20210211","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.4238\/2015.July.28.12","article-title":"IL-6-174G\/C and IL-6-572C\/G polymorphisms are associated with increased risk of coronary artery disease","volume":"14","author":"Li","year":"2015","journal-title":"Genet Mol Res"},{"key":"R29-14-20210211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"R30-14-20210211","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","author":"Babon","year":"2014","journal-title":"Semin Immunol"},{"key":"R31-14-20210211","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","author":"Chavele","year":"2015","journal-title":"J Immunol"},{"key":"R32-14-20210211","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R33-14-20210211","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3227","article-title":"Regulatory immune cells in transplantation","volume":"12","author":"Wood","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R34-14-20210211","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"R35-14-20210211","doi-asserted-by":"crossref","first-page":"e1000006","DOI":"10.1371\/journal.ppat.1000006","article-title":"Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells","volume":"4","author":"Longhi","year":"2008","journal-title":"PLoS Pathog"},{"key":"R36-14-20210211","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/eji.201343746","article-title":"IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo","volume":"44","author":"Smith","year":"2014","journal-title":"Eur J Immunol"},{"key":"R37-14-20210211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-015-0526-4","article-title":"Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response","volume":"17","author":"Kikuchi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R38-14-20210211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/TP.0000000000000437","article-title":"Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization","volume":"98","author":"Kim","year":"2014","journal-title":"Transplantation"},{"key":"R39-14-20210211","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trim.2013.03.003","article-title":"Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization","volume":"28","author":"Wu","year":"2013","journal-title":"Transpl Immunol"},{"key":"R40-14-20210211","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1600-6143.2011.03770.x","article-title":"Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance","volume":"12","author":"Zhao","year":"2012","journal-title":"Am J Transplant"},{"key":"R41-14-20210211","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.4049\/jimmunol.1100766","article-title":"IL-6 promotes cardiac graft rejection mediated by CD4+ cells","volume":"187","author":"Booth","year":"2011","journal-title":"J Immunol"},{"key":"R42-14-20210211","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.4049\/jimmunol.1003774","article-title":"Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells","volume":"187","author":"Fogal","year":"2011","journal-title":"J Immunol"},{"key":"R43-14-20210211","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2015-09-668145","article-title":"Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice","volume":"127","author":"Jin","year":"2016","journal-title":"Blood"},{"key":"R44-14-20210211","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood"},{"key":"R45-14-20210211","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.transproceed.2011.12.032","article-title":"Immunology mini-review: the basics of T(H)17 and interleukin-6 in transplantation","volume":"44","author":"Nakagiri","year":"2012","journal-title":"Transplant Proc"},{"key":"R46-14-20210211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.trim.2009.11.003","article-title":"The dynamic changes of T-bet(+)\/GATA-3(+) and RORgammat(+)\/FOXP3(+) cells in recipient spleens and grafts after rat orthotopic liver transplantation","volume":"22","author":"Xu","year":"2010","journal-title":"Transpl Immunol"},{"key":"R47-14-20210211","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.transproceed.2009.01.092","article-title":"Interleukin-17 and kidney allograft outcome","volume":"41","author":"Crispim","year":"2009","journal-title":"Transplant Proc"},{"key":"R48-14-20210211","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1111\/ajt.13393","article-title":"Intrarenal B cell cytokines promote transplant fibrosis and tubular atrophy","volume":"15","author":"Tse","year":"2015","journal-title":"Am J Transplant"},{"key":"R49-14-20210211","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"key":"R50-14-20210211","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"R52-14-20210211","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R53-14-20210211","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.TP.0000080685.31697.FC","article-title":"Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients","volume":"76","author":"Jordan","year":"2003","journal-title":"Transplantation"},{"key":"R55-14-20210211","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"R56-14-20210211","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","article-title":"Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction","volume":"63","author":"Casiraghi","year":"1997","journal-title":"Transplantation"},{"key":"R57-14-20210211","first-page":"314","article-title":"Interleukin 6 (IL-6) in serum and urine of renal transplant recipients","volume":"71","author":"Van Oers","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"R58-14-20210211","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007890-199103000-00012","article-title":"Differential in situ expression of cytokines in renal allograft rejection","volume":"51","author":"Vandenbroecke","year":"1991","journal-title":"Transplantation"},{"key":"R59-14-20210211","doi-asserted-by":"crossref","first-page":"511","DOI":"10.11622\/smedj.2013174","article-title":"Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients","volume":"54","author":"Sonkar","year":"2013","journal-title":"Singapore Med J"},{"key":"R63-14-20210211","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/imt.15.10","article-title":"Achieving incompatible transplantation through desensitization: current perspectives and future directions","volume":"7","author":"Jordan","year":"2015","journal-title":"Immunotherapy"},{"key":"R64-14-20210211","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1096\/fasebj.4.11.2199284","article-title":"Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF)","volume":"4","author":"Akira","year":"1990","journal-title":"FASEB J"},{"key":"R65-14-20210211","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/gfu233","article-title":"Interleukin-6 in renal disease and therapy","volume":"30","author":"Jones","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R66-14-20210211","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"R67-14-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/19420862.2015.1125583","article-title":"Antibodies to watch in 2016","volume":"8","author":"Reichert","year":"2016","journal-title":"MAbs"},{"key":"R68-14-20210211","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R69-14-20210211","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R70-14-20210211","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"R71-14-20210211","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R73-14-20210211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R74-14-20210211","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J Clin Invest"},{"key":"R75-14-20210211","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R76-14-20210211","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"R77-14-20210211","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"R78-14-20210211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R79-14-20210211","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival benefit with kidney transplants from HLA-incompatible live donors","volume":"374","author":"Orandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R80-14-20210211","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1601379","article-title":"HLA-incompatible kidney transplantation\u2014worth the risk?","volume":"374","author":"Rostaing","year":"2016","journal-title":"N Engl J Med"},{"key":"R81-14-20210211","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","author":"Loupy","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R82-14-20210211","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/ajt.13582","article-title":"Developing new immunosuppression for the next generation of transplant recipients: the path forward","volume":"16","author":"Stegall","year":"2016","journal-title":"Am J Transplant"},{"key":"R84-14-20210211","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/TP.0000000000000872","article-title":"An update on calcineurin inhibitor-free regimens: the need persists, but the landscape has changed","volume":"100","author":"Webber","year":"2016","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:52:28Z","timestamp":1749538348000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201701000-00014"}},"subtitle":["Therapeutic Implications of IL-6 Receptor Blockade"],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001452","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}